[go: up one dir, main page]

ATE110578T1 - Von hydrogel angetriebene verabreichungsvorrichtung. - Google Patents

Von hydrogel angetriebene verabreichungsvorrichtung.

Info

Publication number
ATE110578T1
ATE110578T1 AT90300301T AT90300301T ATE110578T1 AT E110578 T1 ATE110578 T1 AT E110578T1 AT 90300301 T AT90300301 T AT 90300301T AT 90300301 T AT90300301 T AT 90300301T AT E110578 T1 ATE110578 T1 AT E110578T1
Authority
AT
Austria
Prior art keywords
hydrogel
powered
beneficial agents
devices
administration device
Prior art date
Application number
AT90300301T
Other languages
English (en)
Inventor
William John Curatolo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE110578T1 publication Critical patent/ATE110578T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • External Artificial Organs (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90300301T 1989-01-12 1990-01-10 Von hydrogel angetriebene verabreichungsvorrichtung. ATE110578T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29646489A 1989-01-12 1989-01-12

Publications (1)

Publication Number Publication Date
ATE110578T1 true ATE110578T1 (de) 1994-09-15

Family

ID=23142114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90300301T ATE110578T1 (de) 1989-01-12 1990-01-10 Von hydrogel angetriebene verabreichungsvorrichtung.

Country Status (19)

Country Link
US (2) US5516527A (de)
EP (1) EP0378404B1 (de)
JP (1) JPH07119171B2 (de)
KR (1) KR920008702B1 (de)
AT (1) ATE110578T1 (de)
AU (1) AU615129B2 (de)
CA (1) CA2007463C (de)
DE (1) DE69011878T2 (de)
DK (1) DK0378404T3 (de)
ES (1) ES2058775T3 (de)
FI (1) FI900153A7 (de)
HU (1) HUT54038A (de)
IE (1) IE64201B1 (de)
IL (1) IL92966A (de)
MY (1) MY105761A (de)
NO (1) NO900151L (de)
NZ (1) NZ232078A (de)
PT (1) PT92838B (de)
ZA (1) ZA90197B (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
EP0607321A1 (de) * 1991-10-10 1994-07-27 Alza Corporation Osmotische wirkstoffabgabevorrichtung mit hydrophabem wandmaterial
NZ245514A (en) * 1991-12-27 1994-12-22 Merck & Co Inc Controlled release drug delivery device comprising a core and a polymeric coating which is water impermeable but contains apertures to expose the core
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
ZA935569B (en) * 1992-07-31 1994-04-12 Daratech Pty Ltd Controlled release implants
AU682827B2 (en) 1992-09-18 1997-10-23 Astellas Pharma Inc. Sustained-release hydrogel preparation
JPH06256166A (ja) * 1993-01-06 1994-09-13 ▲寛▼治 ▲高▼田 薬物放出制御製剤
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP0758244B2 (de) 1994-05-06 2008-02-13 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
CA2269707C (en) * 1996-10-25 2005-08-16 Edward M. Rudnic Soluble form osmotic dose delivery system
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027888B1 (de) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6228392B1 (en) * 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
US6251432B1 (en) * 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
CZ20022047A3 (cs) 1999-12-23 2003-09-17 Pfizer Products Inc. Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
BR0016707A (pt) 1999-12-23 2002-09-03 Pfizer Prod Inc Forma de dosagem de droga em camadas acionada por hidrogel
EA004370B1 (ru) 1999-12-23 2004-04-29 Пфайзер Продактс Инк. Лекарственная форма с высвобождением лекарства под действием гидрогеля
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
US6296993B1 (en) 2000-06-13 2001-10-02 Eastman Kodak Company Method of providing digitized photographic image
US6361225B1 (en) 2000-06-13 2002-03-26 Eastman Kodak Company Apparatus for providing a photochemical reaction
US6309810B1 (en) 2000-06-13 2001-10-30 Eastman Kodak Company Photochemical delivery article and method of use
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US6770721B1 (en) 2000-11-02 2004-08-03 Surface Logix, Inc. Polymer gel contact masks and methods and molds for making same
CN1204922C (zh) * 2001-02-15 2005-06-08 株式会社三和化学研究所 新的眼科用组合物
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
US20030008007A1 (en) * 2001-04-23 2003-01-09 Jose Gutierrez-Rocca Release pharmaceutical construct for gastric retention
CN100408029C (zh) * 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
CN1864663A (zh) * 2001-11-30 2006-11-22 辉瑞产品公司 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1474144B1 (de) 2002-02-01 2008-08-06 Pfizer Products Inc. Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
AU2003224358A1 (en) * 2002-05-06 2003-11-17 Ranbaxy Laboratories Limited Monocompartment osmotic controlled drug delivery system
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2494234C (en) * 2002-07-29 2009-10-27 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
UY28326A1 (es) * 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
JP5628467B2 (ja) 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. 生体分解性徐放性ドラッグデリバリーシステム
CA2530136C (en) 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
JP2008508414A (ja) * 2004-08-02 2008-03-21 サムヤン コーポレーション ゾル−ゲル遷移が可能な生分解性多重ブロック高分子組成物、及びこれを含有する薬学的組成物
WO2006054152A1 (en) * 2004-11-22 2006-05-26 Ranbaxy Laboratories Limited Monocompartment osmotic-controlled delivery system of doxazosin
JP2007070344A (ja) * 2005-08-11 2007-03-22 Tsukioka:Kk 内服薬
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CA2623940C (en) * 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
NZ543314A (en) * 2005-10-28 2007-08-31 Interag A delivery system where the driving substance contains the active component
EP1959966B1 (de) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
EP2056818B1 (de) 2006-08-11 2011-05-25 The Johns Hopkins University Zusammensetzungen und verfahren für nervenschutz
AU2007284665A1 (en) 2006-08-11 2008-02-21 Payload Systems, Inc. High speed swelling, pressure exerting hemostatic device
EP2526934B1 (de) 2006-09-22 2015-12-09 Pharmacyclics LLC Hemmer der Bruton-Tyrosinkinase
US8812637B2 (en) * 2006-11-28 2014-08-19 International Business Machines Corporation Aggregation of multiple media streams to a user
US20080127272A1 (en) * 2006-11-28 2008-05-29 Brian John Cragun Aggregation of Multiple Media Streams to a User
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2715584A1 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd. Oral controlled release tablet
KR101724161B1 (ko) 2008-08-27 2017-04-06 칼시메디카, 인크 세포내 칼슘을 조절하는 화합물
ES2559029T3 (es) 2009-04-24 2016-02-10 Tissue Tech, Inc. Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2011006066A1 (en) 2009-07-10 2011-01-13 Ironwood Pharmaceuticals, Inc. Cb receptor agonists
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2498764B1 (de) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmentierte hydrogele
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
PH12012501280A1 (en) 2009-12-23 2013-02-04 Ironwood Pharmaceuticals Inc Crth2 modulators
WO2011100324A1 (en) 2010-02-09 2011-08-18 Ironwood Pharmaceuticals Inc. Cannabinoid receptor agonists
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
JPWO2011118454A1 (ja) * 2010-03-23 2013-07-04 リンテック株式会社 固形製剤
EP2558866B1 (de) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
JP5860459B2 (ja) 2010-06-30 2016-02-16 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激薬
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012027710A2 (en) 2010-08-27 2012-03-01 Calcimedica Inc. Compounds that modulate intracellular calcium
ES2572803T3 (es) 2010-11-09 2016-06-02 Ironwood Pharmaceuticals, Inc. Estimuladores de GCs
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
PL2800565T3 (pl) 2012-01-06 2020-09-21 Lundbeck La Jolla Research Center, Inc. Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie
US9046085B2 (en) * 2012-03-14 2015-06-02 Eden Medical, Inc. Miniature pumps
US20150080381A1 (en) 2012-04-12 2015-03-19 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (de) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc-stimulatoren
AU2013323206B2 (en) 2012-09-28 2017-07-20 Fred Hutchinson Cancer Center Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10172791B2 (en) * 2013-03-14 2019-01-08 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
RS59981B1 (sr) 2013-03-15 2020-03-31 Cyclerion Therapeutics Inc Sgc stimulatori
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN104971414A (zh) * 2014-04-01 2015-10-14 黄震山 药物缓释器
EP3134418A4 (de) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York Schnelle und effiziente reaktion zur bioorthogonalen reaktion und borhaltige, zusammen damit nützliche heterocyclen
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
AU2015317824A1 (en) 2014-09-17 2017-03-23 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sGC stimulators
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
ES2760373T3 (es) 2015-02-06 2020-05-13 Univ Washington Compuestos y procedimientos para prevenir o tratar la muerte de células ciliadas sensoriales
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
IL254007B2 (en) 2015-02-27 2024-08-01 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
AU2016262459A1 (en) 2015-05-11 2017-12-21 H. Lundbeck A/S. Methods of treating inflammation or neuropathic pain
JP2018516869A (ja) 2015-05-20 2018-06-28 ティッシュテック,インク. 上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
CA2996177A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
EP3827838B1 (de) 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Hemmung von cytokininduziertem sh2-protein in nk-zellen
PL3405178T3 (pl) 2016-01-19 2025-11-12 Janssen Pharmaceutica Nv Preparaty/kompozycje zawierające inhibitor btk
KR20180101521A (ko) 2016-01-19 2018-09-12 얀센 파마슈티카 엔.브이. Btk 저해제를 포함하는 제형/조성물
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
ES3039958T3 (en) 2016-04-04 2025-10-27 Sinopia Biosciences Inc Treating levodopa-induced dyskinesia using trapidil
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP3957629B1 (de) 2016-07-18 2023-09-06 Arthrosi Therapeutics, Inc. Verfahren zur herstellung von deuteriertem hydroxy-benzbromaron und deren zwischenprodukten
BR112019003973A2 (pt) 2016-08-26 2019-10-08 Curtana Pharmaceuticals Inc inibição de atividade olig2
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
WO2018089328A1 (en) 2016-11-08 2018-05-17 Ironwood Pharmaceuticals, Inc. Treatment of cns diseases with sgc stimulators
WO2018089330A2 (en) 2016-11-08 2018-05-17 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA3043610A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Crystalline forms of a magl inhibitor
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
KR20200086257A (ko) 2017-09-01 2020-07-16 유니버시티 오브 워싱톤 감각 모 세포 사멸 예방 또는 치료용 화합물의 결정질 형태
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
IL286434B1 (en) 2019-03-15 2025-10-01 Unicycive Therapeutics Inc Nicotinell derivatives
BR112021025516A2 (pt) 2020-04-21 2022-11-01 H Lundbeck As Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo
WO2021231322A1 (en) 2020-05-11 2021-11-18 Cleave Therapeutics, Inc. Crystalline forms and formulations of a vcp/p97 inhibitor
EP4263542A1 (de) 2020-12-16 2023-10-25 Biomea Fusion, Inc. Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
CA3218884A1 (en) 2021-05-11 2022-11-17 David Nutt Therapeutic aminoindane compounds and compositions
EP4346788A4 (de) 2021-06-03 2025-04-30 Arcadia Medicine, Inc. Enantiomere entactogenzusammensetzungen und verfahren zu deren verwendung
JP2024531170A (ja) 2021-08-11 2024-08-29 バイオメア フュージョン,インコーポレイテッド 真性糖尿病に対するメニン-mll相互作用の共有結合性阻害剤
JP2024534014A (ja) 2021-08-20 2024-09-18 バイオメア フュージョン,インコーポレイテッド 癌の処置のための不可逆的メニン-MLL阻害剤、N-[4-[4-(4-モルホリニル)-7H-ピロロ[2,3-d]ピリミジン-6-イル]フェニル]-4-[[3(R)-[(1-オキソ-2-プロペン-1-イル)アミノ]-1-ピペリジニル]メチル]-2-ピリジンカルボキサミドの結晶形態
EP4392027A4 (de) 2021-08-23 2025-07-23 Alexander Shulgin Res Institute Inc Fluorierte empathogene
CA3229907A1 (en) 2021-08-23 2023-03-02 Nicholas COZZI Deuterated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
AU2022338032A1 (en) 2021-08-31 2024-03-07 Cerespir Incorporated Co-crystals
IL311211A (en) 2021-09-03 2024-05-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
EP4405318A4 (de) 2021-09-25 2025-11-05 Alexander Shulgin Res Institute Inc Substituierte phenylalkylamine
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
US20250100990A1 (en) 2022-01-19 2025-03-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
CA3244485A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Ltd BRIDGED CYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS
US20250353854A1 (en) 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
EP4551573A1 (de) 2022-07-06 2025-05-14 Oppilan Pharma Ltd. Kristalline formen eines s1p-rezeptormodulators
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 N-[4-[4-(4-嗎啉基)-7h-吡咯並[2,3-d]嘧啶-6-基]苯基]-4-[[3(r)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲醯胺的結晶形式作為menin-mll相互作用的共價抑制劑
WO2024243402A2 (en) 2023-05-24 2024-11-28 Unicycive Therapeutics Inc. Salt forms of nicorandil derivatives
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives
WO2025208111A1 (en) 2024-03-29 2025-10-02 Biomea Fusion, Inc. Heterocyclic glp-1r agonists

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4180073A (en) * 1977-08-29 1979-12-25 Alza Corporation Device for delivering drug to biological environment
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4320759A (en) * 1980-04-28 1982-03-23 Alza Corporation Dispenser with diffuser
US4350271A (en) * 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4663286A (en) * 1984-02-13 1987-05-05 Damon Biotech, Inc. Encapsulation of materials
US4772474A (en) * 1985-08-09 1988-09-20 Alza Corporation Dispenser with internal arrangement of lamina means for dispensing beneficial agent
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
CA1266827A (en) * 1984-06-20 1990-03-20 Merck & Co., Inc. Controlled porosity osmotic pump
US4608048A (en) * 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
CA1242394A (en) * 1985-03-07 1988-09-27 Neil B. Graham Controlled release device
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
DE3769707D1 (de) * 1986-06-17 1991-06-06 Recordati Chem Pharm Therapeutisches system mit geregelter wirkstoffabgabe.
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3629994A1 (de) * 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel

Also Published As

Publication number Publication date
NO900151L (no) 1990-07-13
IE64201B1 (en) 1995-07-12
MY105761A (en) 1995-01-30
EP0378404A2 (de) 1990-07-18
HU900108D0 (en) 1990-03-28
DE69011878D1 (de) 1994-10-06
CA2007463C (en) 1995-01-17
PT92838B (pt) 1996-02-29
AU615129B2 (en) 1991-09-19
FI900153L (fi) 1990-07-13
FI900153A7 (fi) 1990-07-13
KR920008702B1 (ko) 1992-10-08
JPH02229110A (ja) 1990-09-11
IL92966A (en) 1995-07-31
EP0378404A3 (en) 1990-10-03
IE900104L (en) 1990-07-12
EP0378404B1 (de) 1994-08-31
KR900011486A (ko) 1990-08-01
AU4787790A (en) 1990-07-19
FI900153A0 (fi) 1990-01-11
US5516527A (en) 1996-05-14
NZ232078A (en) 1991-02-26
IL92966A0 (en) 1990-09-17
DE69011878T2 (de) 1994-12-15
NO900151D0 (no) 1990-01-11
DK0378404T3 (da) 1994-10-03
CA2007463A1 (en) 1990-07-12
ZA90197B (en) 1991-07-31
JPH07119171B2 (ja) 1995-12-20
PT92838A (pt) 1990-07-31
ES2058775T3 (es) 1994-11-01
HUT54038A (en) 1991-01-28
US5792471A (en) 1998-08-11

Similar Documents

Publication Publication Date Title
ATE110578T1 (de) Von hydrogel angetriebene verabreichungsvorrichtung.
DE3866817D1 (de) Knochenzement zur kontrollierten abgabe von wirkstoffen.
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
ES2168395T3 (es) Nueva formulacion antitrombotica, procedimiento para su preparacion y utilizacion de la misma.
DK0457849T3 (da) Klæbemiddel til elektrotransport
KR900011485A (ko) 리오트로픽 액정에 의해 작동되는 분배 장치
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
DK561589D0 (da) Flydende oralt farmaceutisk praeparat
DE59000613D1 (de) Pflaster zur transdermalen anwendung.
AU7071487A (en) Chlorpheniramine therapy
DE69231263D1 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen
DK392288A (da) Human monoklonale antistoffer samt profylaktiske og terapeutiske midler mod infrektioese sygdomme, der indeholder samme som aktiv bestanddel
ES2055847T3 (es) Agente fijador de fosfato para administracion por via oral.
DE59712215D1 (de) Transdermales therapeutisches system mit einer östriol enthaltenden bisphosphatekombination
DK594889D0 (da) Reservoir til styret medikamentafgivelse, indretning indeholdende saadant reservoir samt fremgangsmaade til fremstilling og anvendelse af indretningen
ES1011913Y (es) Dispositivo para el rellenado de boletos de la loteria primitiva.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee